Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance;Implication des transcrits alternatifs de la caspase 3 et de la survivine dans la chimiorésistance

Bulletin du Cancer

Volumn 92, Issue 3, 2005, Pages 219-226

  Vegran, Frédérique ^a   Boidot, Romain ^a   Oudin, Claire ^a   Riedinger, Jean Marc ^a   Lizard Nacol, Sarah ^a  

^a INSERM   (France)

Author keywords

Apoptosis; Caspase 3; Chemoresistance; Splice variant transcript; Survivin; Tumor progression

Indexed keywords

CASPASE 3; CASPASE 3S; INHIBITOR OF APOPTOSIS PROTEIN; SURVIVIN; SURVIVIN 2B; SURVIVIN 3B; SURVIVIN DELTA EX3; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASPASE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ALTERNATIVE RNA SPLICING; APOPTOSIS; CANCER; CARCINOGENESIS; CHEMOSENSITIVITY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; EXON; GENE DELETION; HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR CELL; TUMOR GROWTH; DISEASE COURSE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

ALTERNATIVE SPLICING; APOPTOSIS; CASPASE 3; CASPASES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 17144388194     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancel-genetics and chemotherapy. Cell 2002; 108: 153-64.
2. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev 1999; 13: 239-52.
3. Mignon A, Rouquet N, Joulin V. Les caspases, les protéases à cystéine de l'apoptose: un enjeu thérapeutique pour demain? Med Sci (Paris) 1998; 14: 9-17.
4. Bettaieb A, Sordet O, Belon JP, Solary E. Apoptose et chimiothérapie. Bull Cancer 1999; 86: 41-6.
5. Couzinet A, Herincs Z, Huebert AO. Régulation de la mort cellulaire programmée: vers une conception plus dynamique. Med Sci (Paris) 2002; 18: 841-52.
6. Ségal-Bendirdjian E, Hillion J, Belmokhtar CA. Actualités sur les voies de signalisation de l'apotose: nouvelles cibles de la chimiothérapie. Bull Cancer 2003; 90: 9-17.
7. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003; 12: 481-6.
8. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 2000; 25: 228-38.
9. Solier S, Lansiaux A, Logette E, Wu J, Soret J, Tazi J, et al. Topoisomerase I and II inhibitors control caspases-2 premessager RNA splicing in human cells. Mol Cancer Res 2004; 2: 53-61.
10. Mercatante D, Kole R. Modification of alternative splicing pathway as a potential approach to chemotherapy. Pharmacol Ther 2000; 85: 237-43.
11. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357-60.
12. Zhan Q, Jin S, Ng B, Plisket J, Shangary S, Rathi A, et al. Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis. Oncogene 2002; 21: 5335-45.
13. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC, et al. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 2000; 60: 4386-90.
14. Tiso N, Pallavicini A, Muraro T, Zimbello R, Apolloni E, Valle G, et al. Chromosomal localization of the human genes, CPP32, Mch2, Mch3, and Ich-1, involved in cellular apoptosis. Biochem Biophys Res Commun 1996; 225: 983-9.
15. Liu W, Wang G, Yakovlev AG. Identification and functional analysis of the rat caspases-3 gene promoter. J Biol Chem 2002; 277: 8273-8.
16. Faleiro L, Lazebnik Y. Caspases disrupt the nuclear-cytoplasmic barrier. J Cell Biol 2000; 151: 951-9.
17. Huang Y, Shin NH, Sun Y, Wang KK. Molecular cloning and characterization of a novel caspase-3 variant that attenuates apoptosis induced by proteasome inhibition. Biochem Biophys Res Commun 2001; 283: 762-9.
18. Végran F, Oudin C, Boidot R, Hahnel L, Cadouot M, Riedinger JM, et al. Analyse de l'expression de la caspase-3 et de son transcript alternative caspase-3s dans le cancer du sein. Revue 2005; (sous presse).
19. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, et al. Overexpression of caspases-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquited drug resistance. Oncogene 2001; 20: 2749-60.
20. Vakkala M, Paakko P, Soini Y. Expression of caspase 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br J Cancer 1999; 81: 592-9.
21. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002; 21: 8843-51.
22. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res 2002; 8: 2024-34.
23. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002; 86: 737-43.
24. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
25. Song Z, Yao X, Wu MJ. Direct interaction between survivin and Smac/DIABLO is essentiel for the anti-apoptotic activity of survivin during taxol-induced apoptosis. Biol Chem 2003; 278: 23130-40.
26. Ambrosini G, Adida C, Altieri DC. A novel anti-apotosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
27. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177-82.
28. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003; 5: 447-52.
29. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the antiapoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-57.
30. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-22.
31. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2002; 62: 7379-81.
32. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 2000; 35: 550-3.
33. Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004; 23: 419-29.
34. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-102.
35. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, et al. identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 2004; 314: 902-7.
36. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002; 9: 1334-42.
37. Chakravarti A, Noll E, Black PM, Finkelstein DM, Dyson NJ, et al. Quantitatively determined survivin expression levels are prognostic value in human gliomas. J Clin Oncol 2002; 20: 1063-8.
38. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003; 88: 1077-83.
39. Wang L, Zhang GM, Feng ZH. Down-regulation of survivin expression reversed multidrug resistance in adriamycine-resistant HL-60/ADR cell line. Acta Pharmacol Sin 2003; 24: 1235-40.
40. Chiou SK, Jones MK, Tarnawski AS. Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 2003; 9: 125-9.
41. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, wich is independent of taxol-mediated G2/M arrest. J Biol Chem 2004; 279: 15196-203.
42. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-12.
43. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003; 99: 738-45.
44. Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002; 38: 2316-24.
45. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541-52.
46. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamigushi K, Sato T, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9.